Insider Trading April 21, 2026 04:55 PM

Arlo CFO Disposes $380K in Stock as Company Posts Strong Quarter and Announces Buyback

Kurtis Binder sold 25,000 shares under a 10b5-1 plan; Arlo reports Q4 beat, closes Aloe Care Health deal and greenlights a $50 million repurchase program

By Sofia Navarro ARLO
Arlo CFO Disposes $380K in Stock as Company Posts Strong Quarter and Announces Buyback
ARLO

Kurtis Joseph Binder, chief financial officer of Arlo Technologies, sold 25,000 shares of the company’s common stock on April 17, 2026, generating proceeds of $379,857. The transaction was carried out under a Rule 10b5-1 plan adopted in November 2025. Following the sale, Binder directly holds 564,885 shares. The sale comes against a backdrop of strong recent returns for Arlo, a high trailing price-to-earnings ratio and fresh corporate actions including an acquisition and a $50 million share buyback program.

Key Points

  • Arlo CFO Kurtis Joseph Binder sold 25,000 shares on April 17, 2026 for total proceeds of $379,857 under a Rule 10b5-1 plan.
  • Arlo reported Q4 2025 results that beat estimates - EPS $0.22 versus $0.16 expected and revenue of $141.3 million versus $133.95 million forecast.
  • The company completed the acquisition of Aloe Care Health and its board authorized up to $50 million for an open-market buyback program through 2027.

Transaction details and mechanics

Kurtis Joseph Binder, Arlo Technologies, Inc.'s chief financial officer, executed a sale of 25,000 shares of the company’s common stock on April 17, 2026. The shares traded at a weighted average price of $15.1943, with individual executions occurring between $15.00 and $15.30. The total proceeds from the disposition were $379,857.

The filing indicates the sale was made pursuant to a Rule 10b5-1 trading arrangement Mr. Binder put in place on November 28, 2025. After completing this transaction, Mr. Binder is reported to directly own 564,885 shares of Arlo common stock.


Where the stock stands

Arlo’s shares have appreciated substantially over the past 12 months, returning 66% over that period. At the same time, the company’s shares trade at a trailing price-to-earnings ratio of 106 and the company carries a market capitalization of $1.59 billion.

Separately, an InvestingPro analysis cited in company filings or commentary indicates that Arlo currently appears overvalued relative to its Fair Value.


Recent corporate developments

Arlo disclosed robust financial results for the fourth quarter of 2025. The company reported earnings per share of $0.22, beating the consensus estimate of $0.16, and revenue of $141.3 million, which exceeded the forecasted $133.95 million.

In addition to the quarterly beat, Arlo completed its acquisition of Aloe Care Health. The transaction adds medical alert services and fall prevention technology to Arlo’s product mix, expanding its footprint in connected care and smart security offerings.

Arlo’s board has also approved a stock repurchase program authorizing up to $50 million of open market purchases through 2027. The company said the buyback will be executed via open market activity.


Context and takeaways

The insider sale was implemented under a pre-established trading plan and leaves Mr. Binder with a substantial direct ownership position in Arlo. At the same time, the company is reporting stronger-than-expected results, has added a healthcare-oriented business line through acquisition, and has committed capital to a limited buyback program. Market metrics cited in filings or analysis suggest the shares trade at a high P/E and may be valued above InvestingPro’s Fair Value estimate.

Risks

  • Valuation risk - Arlo trades at a trailing P/E of 106 and InvestingPro analysis indicates the stock appears overvalued relative to its Fair Value, which may affect investor expectations in the technology and consumer electronics sectors.
  • Execution and integration risk - The recent acquisition of Aloe Care Health expands Arlo’s product set into medical alert services and fall prevention technology; successful integration is necessary to realize strategic benefits, impacting smart security and connected-care segments.
  • Limited buyback scope - The authorized repurchase program is capped at $50 million through 2027, which may offer constrained support to the stock given the company’s $1.59 billion market capitalization.

More from Insider Trading

Oasis Management Disposes $1.46M in Stratus Properties Shares Over Mid-April Trades Apr 21, 2026 Williams-Sonoma CEO Sells $3.0M in Stock Under Prearranged Trading Plan Apr 21, 2026 AEHR Test Systems EVP Vernon Rogers Sells $450,000 in Stock; Company Posts Record Order and Raises Capital Apr 21, 2026 Ouster CTO Disposes of $3.31 Million in Shares After Exercising Options Apr 21, 2026 Opaleye Management Disposes of $336,982 in SANUWAVE Health Stock Across April Trades Apr 21, 2026